George Church Startup Nets $60M to Take Non-Standard Amino Acids to the Clinic

GRO Biosciences will use the Series B funds to launch a Phase I trial for ProGly-Uricase, its investigational therapy for gout.

GRO Biosciences, which was born out of pioneering genetics research from George Church’s lab at Harvard, closed a Series B funding round on Friday, with a $60.3 million raise to help the company advance its pipeline and further develop its platform.